AtriCure, Inc.

NasdaqGM ATRC

AtriCure, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2024: USD 447.57 M

AtriCure, Inc. Revenue is USD 447.57 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 17.56% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • AtriCure, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 380.73 M, a 20.65% change year over year.
  • AtriCure, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 315.57 M, a 21.92% change year over year.
  • AtriCure, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 258.84 M, a 23.18% change year over year.
  • AtriCure, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 210.13 M, a -5.51% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
NasdaqGM: ATRC

AtriCure, Inc.

CEO Mr. Michael H. Carrel
IPO Date Aug. 5, 2005
Location United States
Headquarters 7555 Innovation Way
Employees 1,200
Sector Health Care
Industries
Description

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Similar companies

AXGN

AxoGen, Inc.

USD 18.24

-0.06%

CNMD

CONMED Corporation

USD 67.79

-2.46%

LMAT

LeMaitre Vascular, Inc.

USD 95.85

1.78%

ANGO

AngioDynamics, Inc.

USD 11.80

-5.30%

StockViz Staff

January 15, 2025

Any question? Send us an email